How profitable is Haemonetics Corporation (HAE)?

In FY 2025 (10-K), HAE converted $1.3B of revenue into a 59% gross margin, 11.7% operating margin, and $260.4M in free cash flow (19.5% FCF margin).

Stock Ratings / Health Care / HAE / financials

STVN (54) MMSI (68) MMED (44) HTFL (53) ⌘ Pro Terminal →

Haemonetics Corporation (HAE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$120.14 +0.41% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $120.52

Haemonetics Corporation (HAE) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (59.0% gross margin, 8% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $5.44B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HAE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HAE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Haemonetics Corporation (NYSE: HAE) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $120.14 (+0.41% 1D, market cap $5.44B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, HAE ranks #38 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HAE compare to STVN and MMSI in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), HAE carries a Roarable B (74/100 RQD), trailing P/E of N/A, gross margin of 59.0%, and ROIC of 8.4%. By comparison, STVN (Stevanato Group S.p.A.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.29B) and MMSI (Merit Medical Systems Inc.) posts a C+ grade (68/100 RQD, P/E 43.4x, ROIC 7.8%, cap $5.17B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HAE?

▼

Per HAE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-28, CIK 0000313143), Haemonetics Corporation generated $1.33B in revenue (-2.0% YoY), $97.3K in net income, and $260.4M in free cash flow against $2.49B in total assets and $920.0M in total debt. Key quantitative strengths: Strong cash generator (59.0% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $120.51 (+0.31%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 19.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HAE)Realized 20D OHLCV Swing Band: ±5.8%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY HAE SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (23% of score)

20D Institutional Volume Accumulation (±5.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 3.89 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution13/20 pts (-7 pt drag)

Cannibal Buyback (-1.52% YoY Shares) & executive Form 4 sales trim 7 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$121.11-3.3% Next Q

Q2 (-2Q)

Grade A-$117.11+1% Next Q

Q3 (-1Q)

Grade B+$118.32+1.5% Next Q

Current

Grade B$120.14+7.3% Hist 90D α

Trajectory: A (82) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the HAE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, HAE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 56.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($110.65) or 200D SMA ($79.35) invalidates the momentum regime and cuts Target Base ($128.79) toward Bear Floor ($98.51).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HAE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HAE Beats Next Quarter EPS Consensus (Dec 26, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How HAE Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$260.4M (19.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.31B

FY24

Rev $1.36B

FY25

Rev $1.33B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.33B	59%	11.7%	$97.3K	$260.4M	8.4%
FY 2024	$1.36B	55%	16.3%	$167.7K	$142.4M	9.7%
FY 2023	$1.31B	59%	12.6%	$117.6M	$122.8M	7.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HAE)

✓Walkthrough of HAE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HAE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +117.17%▲ ASCENDING CHANNEL

2026-11-03O $119.8H $120.1L $119.7C $120.1VOL 453.4K

RES: $130.1SUP: $111.0SMA50: $110.7SMA200: $79.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HAE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HAE Butterfly Map → + Track HAE →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

30.8%/yr Implied 5Y Growth

vs. -2.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HAE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HAE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HAE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HAE)

Health Care Rank #38 of 1015 ⚔️ STVN vs HAE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HAE vs. STVN, MMSI, MMED, HTFL)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Haemonetics Corporation (HAE) ranks #38 by composite RQD confidence (74/100, grade B) and #151 by equity capitalization ($5.44B). Within this direct 5-issuer industry benchmark cohort, MMSI leads on earnings valuation at 43.4x trailing P/E, while HAE leads on capital efficiency and profitability with 8.4% ROIC and 59.0% gross margin. HAE currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HAE ACTIVE Haemonetics Corporation	B	74/100	—	59.0%	8.4%	+0.41%	$5.44B	Benchmark Subject
STVN Stevanato Group S.p.A.	D+	54/100	—	—	—	+1.86%	$5.29B	/stvn-vs-hae →
MMSI Merit Medical Systems Inc.	C+	68/100	43.4x	48.7%	7.8%	-2.24%	$5.17B	/mmsi-vs-hae →
MMED MiniMed Group Inc.	D	44/100	—	54.2%	-3.9%	+3.39%	$5.14B	/mmed-vs-hae →
HTFL Heartflow Inc.	D+	53/100	—	76.8%	-12.0%	-7.72%	$5.13B	/htfl-vs-hae →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-28 • CIK 0000313143 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-28), Haemonetics Corporation (HAE) reported GAAP revenue of $1.33B (-2.0% vs. FY2024 revenue of $1.36B , and +1.9% cumulative change since FY2023) , GAAP net income of $97.3K, operating cash flow of $293.2M, and free cash flow of $260.4M (+82.8% YoY). On the balance sheet, HAE closed FY2025 with $2.49B in total assets against $920.0M in total debt (Altman Z-Score: 3.89, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-28	$1.33B	$97.3K	$293.2M	$260.4M	$2.49B	$920.0M
FY2024 (FY)	2025-03-29	$1.36B	$167.7K	$181.7M	$142.4M	$2.53B	$1.22B
FY2023 (FY)	2024-03-30	$1.31B	$117.6M	$181.8M	$122.8M	$3.00B	$701.4M

3. HAE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HAE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HAE compare to STVN and MMSI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HAE?

Where is HAE trading relative to its 50-day, 200-day, and 52-week technical levels?

HAE last traded at $120.14 (+0.41% on volume of 678,644 shares), positioning the stock +8.58% above its 50-day simple moving average ($110.65) and +51.41% above its 200-day simple moving average ($79.35). Across its 52-week range of $49.24 to $123.77, HAE sits at the 95.1% percentile with a 14-day RSI of 63.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.8% ($113.17 to $127.11).

Direct Sub-Reports: HAE RQD Cockpit HAE 12M Forecast HAE Earnings & Move HAE Dividends & DRIP HAE Insiders & 13F HAE Whale Options HAE Profit Sankey HAE News & Why

ROARABLE RATING BRIEF • RQD 74/100 (B) ✓ SEC XBRL & RQD VERIFIED

HAE — Haemonetics Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2026-03-28

1. Roarable Rating Brief: What This Means to a Prospective Investor

Haemonetics Corporation (HAE) earns a live Roarable RQD composite score of 74/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $120.14 (+0.41% 1D, market capitalization $5.44B).

Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 8.4%, gross margin of 59.0%, operating margin of 11.7%, and free cash flow yield of 4.78%.
Whale 13F & Options Flow (17/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (13/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.89, Piotroski F-Score of 7/9, and Debt/Equity of 1.01x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Haemonetics Corporation (HAE) is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry, with a market capitalization of $5.5B. —: product lines, customer base, and specific revenue mechanics beyond the sector and industry classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-28), Haemonetics Corporation (HAE) reported $1.33B in annual revenue (up from $1.36B in FY2024, -2.0% YoY) and $97.3K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.31B revenue, $117.6M net income) through FY2025, HAE scaled operating cash flow to $293.2M and free cash flow to $260.4M, backed by $2.49B in total assets against $920.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 74/100): Strong cash generator (59.0% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $49.24 – $123.77 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 32.5x EV/EBITDA against 11.7% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The news section references a CSL Plasma supply deal, which suggests a customer or partner relationship, but the source does not establish its structure or dependency weight.

Key Question #1: Can HAE sustain or expand its 11.7% operating margin and 8.4% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.33B and free cash flow of $260.4M, how will capital allocation balance growth reinvestment against $920.0M in total debt?
Key Question #3: How sensitive is HAE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HAE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Haemonetics Corporation (HAE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HAE Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 22h ago

Haemonetics stock surges 17% on CSL Plasma supply deal update

Yahoo Finance report covering Haemonetics Corporation (HAE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

Haemonetics gains after update on CSL supply deal (HAE:NYSE)

Seeking Alpha report covering Haemonetics Corporation (HAE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Haemonetics Corporation Stock 12‑Month Price Target Raised to $120, Implies 18% Upside

TradingView report covering Haemonetics Corporation (HAE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

Yahoo Finance report covering Haemonetics Corporation (HAE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Timothy Sykes • 1d ago

Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123

Timothy Sykes report covering Haemonetics Corporation (HAE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Haemonetics Corporation Estimates – NYSE:HAE

TradingView report covering Haemonetics Corporation (HAE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST marketscreener.com • 1d ago

Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027

marketscreener.com report covering Haemonetics Corporation (HAE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Haemonetics advances 17% on CSL supply deal (HAE:NYSE)

Seeking Alpha report covering Haemonetics Corporation (HAE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HAE Bull vs. Bear Conversation Board — What's Your Call at $120.14?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HAE 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $150.76 (+26.0%)

📌 Pinned Debate

Institutional whale flow (17/20) and a Piotroski F-Score of 7/9 with Altman Z of 3.89 signal strong institutional support and sound for

Long HAE at $119.65 targeting $150.76. Institutional whale flow (17/20) and a Piotroski F-Score of 7/9 with Altman Z of 3.89 signal strong institutional support and sound forensic health.. Institutional whale score is 17/20 and the risk/reward vs. the $49.96 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@BreakoutHunter Agree on the RQD 74/100 quality, though with 1.0 beta I'm scaling in with half-size at $119.65 and keeping dry powder in case we test $111.27.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $94.52 (-21.0%)

Spot @ $119.65

Net margin of 0% and an EV/EBITDA of 32.5 leave the stock priced at a premium with little reported net earnings to support it.

Sitting on the sidelines or leaning short HAE above $119.65. Net margin of 0% and an EV/EBITDA of 32.5 leave the stock priced at a premium with little reported net earnings to support it.. Until Fundamental Cash Engine (15/20) and FCF yield (4.78%) inflect higher, upside is capped near $123.77.